Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients with acute anterior wall myocardial infarction.
暂无分享,去创建一个
G. Rosano | F. Romeo | E. Martuscelli | M. Comito | C. Bianco | F. de Luca | C. Colistra | N. Cardona | F. Miceli | V. Rosano
[1] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[2] R. Magorien,et al. Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction. , 1992, The American journal of cardiology.
[3] J. Wójcik,et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. , 1992, Journal of the American College of Cardiology.
[4] U. Tebbe,et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS) , 1992, Journal of the American College of Cardiology.
[5] K. Swedberg,et al. Dynamic QRS complex and ST segment vectorcardiographic monitoring can identify vessel patency in patients with acute myocardial infarction treated with reperfusion therapy. , 1991, American heart journal.
[6] S. Hohnloser,et al. Assessment of coronary artery patency after thrombolytic therapy: accurate prediction utilizing the combined analysis of three noninvasive markers. , 1991, Journal of the American College of Cardiology.
[7] J. Mehta,et al. Concurrent nitroglycerin administration decreases thrombolytic potential of tissue-type plasminogen activator. , 1991, Journal of the American College of Cardiology.
[8] J. Mehta,et al. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis. , 1990, Circulation.
[9] U. Tebbe,et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.
[10] J. Stamler,et al. Synergistic Disaggregation of Platelets by Tissue-Type Plasminogen Activator, Prostaglandin El9 and Nitroglycerin , 1989, Circulation research.
[11] B. Sobel,et al. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration. , 1989, Circulation.
[12] H. Gold,et al. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. , 1988, Circulation.
[13] B. Sobel,et al. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. , 1988, Circulation.
[14] S. Forman,et al. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. , 1987, Journal of the American College of Cardiology.
[15] R. W. Brower,et al. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. , 1987, The American journal of cardiology.
[16] R Roberts,et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.
[17] M. Krucoff,et al. Noninvasive detection of coronary artery patency using continuous ST-segment monitoring. , 1986, The American journal of cardiology.
[18] E. Kruithof,et al. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. , 1984, Blood.
[19] P. Rentrop,et al. Patterns of creatine kinase release during acute myocardial infarction after nonsurgical reperfusion: comparison with conventional treatment and correlation with infarct size. , 1984, Journal of the American College of Cardiology.
[20] R. Ideker,et al. Evaluation of a QRS scoring system for estimating myocardial infarct size. III. Correlation with quantitative anatomic findings for inferior infarcts. , 1984, The American journal of cardiology.
[21] J. Mehta,et al. Comparative Effects of Nitroprusside and Nitroglycerin on Platelet Aggregation in Patients with Heart Failure , 1980, Journal of cardiovascular pharmacology.